**Demographic and socioeconomic data**

- **Population**: 23.4 million
- **GNI per capita, PPP (2015)**: $3,070
- **Health expenditure, total (% of GDP) (2014)**: 4.1%
- **Life expectancy at birth (2015-2020)**: 59 years
- **Total fertility rate (births per woman) (2015-2020)**: 4.6
- **Number of births (thousands) (2015-2020)**: 4,327
- **Human Development Index Value (2015)**: 0.52

**Estimated number of people newly infected with HIV**

- **Average (2010-2016)**: 31,000 [28,000 - 35,000]

**Estimated number of deaths due to AIDS**

- **Average (2010-2016)**: 33,000 [30,000 - 36,000]

**Epidemiological HIV data**

- **Number of deaths due to HIV**: 2,900 [2,500 - 3,300]
- **Number of people living with HIV**: 56,000 [47,000 - 65,000]
- **Number of children living with HIV**: 5,000 [4,000 - 6,000]
- **Number of people newly infected with HIV**: 32,000 [22,000 - 41,000]

**Antiretroviral therapy (ART)**

- **Estimated ART coverage**: 37% [31% - 43%]
- **Estimated ART coverage (children, 0-14)**: 18% [14% - 23%]

**90-90-90 progress towards 2020 targets**

- **PLHIV diagnosed**: 58% 37% 19%
- **PLHIV receiving ART**: 74% 60% 40%
- **PLHIV virally suppressed**: 19% 15% 10%

**Elimination of mother-to-child transmission (EMTCT)**

- **Antenatal care coverage**: 83% 2014
- **Antenatal care coverage**: 59% 2014
- **% of pregnant women living with HIV who received antiretrovirals for PMTCT**: 100% 2013
- **% of infants born to women living with HIV who received antiretrovirals for PMTCT**: 74% [56% - 90%] 2016
- **% of women diagnosed with HIV who were virologically suppressed**: 90% [85% - 95%] 2016

*Tracing indicators for elimination of mother-to-child transmission. A colour scheme (green, orange, red) is used to indicate if the country is on target to meet 2020 targets: ≥90% ≥95% <5%.
Cameroon
HIV Country Profile: 2016

Key populations

<table>
<thead>
<tr>
<th>Needles distributed per person who inject drugs per year</th>
<th>...</th>
</tr>
</thead>
<tbody>
<tr>
<td>Percentage condom use among sex workers with most recent client</td>
<td>96%</td>
</tr>
<tr>
<td>Percentage of men reporting using a condom the last time they had anal sex with a male partner</td>
<td>78%</td>
</tr>
<tr>
<td>HIV prevalence among sex workers (%)</td>
<td>24%</td>
</tr>
</tbody>
</table>

Median annual price of ARV drug regimens for adults

- **First line**
  - [ZDV+3TC+NVP] [150+200+300]
  - [TDF+FTC+EFV] [600+200+300]
  - [TDF+3TC+EFV] [600+300+300]
- **Second line**
  - [ZDV+3TC] + [LPV/r]
  - [TDF+3TC] + [LPV/r]
  - [TDF+FTC] + [ATV/r]

National HIV policies and plans

- Implementation of national policy on HIV self-testing (HIVST) : No policy
- Treatment initiation threshold children : Treat All regardless of age
- Treatment initiation threshold adults and adolescents : Treat All regardless of CD4 count
- Implementation of Treat All adults and adolescents : Implemented countrywide
- Dolutegravir (DTG) as part of 1st line ARVs for adults and adolescents : TDF/3TC(FTC)/EFV first line ARVs only
- Implementation of lifelong ART to pregnant & breastfeeding women : Implemented countrywide
- Implementation of national policy on viral load monitoring : Fully implemented
- Completion of HIV services cascades : Completed a national HIV cascade
- Adaptation of WHO Key Population guidelines in national plans : Fully
- National M&E plan or strategy for HIV : Yes, and updated in the past two years
- Method to de-duplicate key data (i.e. unique identifiers) : No
- Nationally-representative quality assessment of facility-level ART data : No

Sources: Global AIDS Monitoring (UNAIDS/WHO/UNICEF), Spectrum estimates (UNAIDS/WHO) and WHO HIV Country Intelligence Tool, 2017